{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:32:51Z","timestamp":1790469171930,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2012.03.011","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T13:00:33Z","timestamp":1331989233000},"page":"3710-3716","source":"Crossref","is-referenced-by-count":108,"title":["Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines"],"prefix":"10.1016","volume":"30","author":[{"given":"Shamez N.","family":"Ladhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Kaczmarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Mallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Guiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne S.","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.03.011_bib0005","doi-asserted-by":"crossref","first-page":"c3209","DOI":"10.1136\/bmj.c3209","article-title":"Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance","volume":"340","author":"Visintin","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/adc.2006.102384","article-title":"Emergency management of meningococcal disease: eight years on","volume":"92","author":"Pollard","year":"2007","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","author":"Gasparini","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bmj.320.7229.213","article-title":"Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis","volume":"320","author":"Reacher","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0045","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/INF.0b013e3181d3ce32","article-title":"Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children","volume":"29","author":"Levy","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0009922809347797","article-title":"Epidemiology and meningococcal serogroup distribution in the United States","volume":"49","author":"Hershey","year":"2010","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0055","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/hv.7.8.16270","article-title":"Meningococcal disease: the advances and challenges of meningococcal disease prevention","volume":"7","author":"Yogev","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0060","unstructured":"Department of Health Annual HPV vaccine coverage in England in 2009\/2010. Gateway Reference 15439; 2011."},{"key":"10.1016\/j.vaccine.2012.03.011_bib0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0070","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(99)00252-4","article-title":"Meningococcal conjugate vaccines: new opportunities and new challenges","volume":"354","author":"Maiden","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0080","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/oxfordjournals.molbev.a026061","article-title":"The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis","volume":"16","author":"Feil","year":"1999","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0085","doi-asserted-by":"crossref","first-page":"e1001277","DOI":"10.1371\/journal.pgen.1001277","article-title":"The transposon-like Correia elements encode numerous strong promoters and provide a potential new mechanism for phase variation in the meningococcus","volume":"7","author":"Siddique","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0095","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/IAI.00181-09","article-title":"Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains","volume":"77","author":"Beddek","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1473-3099(06)70584-9","article-title":"No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales","volume":"6","author":"Trotter","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0115","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmj.324.7341.809","article-title":"Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0120","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.03.011_bib0125","doi-asserted-by":"crossref","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","article-title":"Meningococcal carriage and disease \u2013 population biology and evolution","volume":"27","author":"Caugant","year":"2009","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2012.03.011_bib0130","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.23.19885-en","article-title":"Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010","volume":"16","author":"Thulin Hedberg","year":"2011","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0135","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3201\/eid1406.071357","article-title":"Serogroup Y meningococcal disease, Colombia","volume":"14","author":"Ines-Agudelo","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3201\/eid1801.110901","article-title":"Invasive meningococcal capsular group Y disease, England and wales, 2007\u20132009","volume":"18","author":"Ladhani","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0145","unstructured":"Centers for Disease Control and Prevention. Activebacterial core surveillance (ABCs) report. Emerging infections program network. Neisseria meningitidis; 2009 [October 2010 File \u2013 17 November 2010]."},{"key":"10.1016\/j.vaccine.2012.03.011_bib0150","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0155","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1155\/2009\/871071","article-title":"Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection","volume":"20","author":"Le Saux","year":"2009","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0160","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1017\/S095026880999104X","article-title":"Emergence and disappearance of W135 meningococcal disease","volume":"138","author":"Wilder-Smith","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2012.03.011_bib0165","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1128\/IAI.01311-09","article-title":"The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease","volume":"78","author":"Fransen","year":"2010","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12003593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12003593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T12:15:45Z","timestamp":1641298545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12003593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0264410X12003593"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}